Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemoradiotherapy for Head and Neck Cancer
NCT00203905Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jan 2004
- Primary completion
- Nov 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in head and neck cancer (HNC) (2 arms), sponsored by University of Chicago. Primary endpoint: Time to Progression. Started Jan 2004; status: completed.
02
Drugs
bevacizumab
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00203905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203905.